

REMARKS

Applicants have canceled Claims 19 and 22-27 as discussed below.

Restriction Requirement under 35 U.S.C. 121


The Office Action requires restriction to one of the following groups:

- Group I: Claims 15-18 and 20, drawn to products of formula (I)
- Group II: Claims 19 and 22, drawn to a process of preparing products of formula (I)
- Group III: Claim 23, drawn to products of formula (III)
- Group IV: Claim 24, drawn to products of formula (V)
- Group V: Claim 25, drawn to products of formula (VI)
- Group VI: Claim 26, drawn to products of formula (VIII)
- Group VII: Claim 27, drawn to products of formula (XIV)


Applicants note by way of comment that the Office Action did not refer to Claim 21, which is drawn to a method of use, within the aforementioned groups. Applicants will address this omission in the following discussion. The Office Action also requires an election of a single disclosed species from the elected group for the purpose of initial examination.

Applicants elect Group I with traverse with respect to Claim 21 but without traverse with respect to the other groups. Applicants have accordingly canceled Claims 19 and 22-27. Although Applicants request joinder of Claim 21 with the claims of Group I, Applicants have identified Claim 21 above as having been withdrawn. Applicants' traversal is based on the inherent relatedness of the claimed products of Group I and the inherent properties such products exhibit.

Applicants also elect for initial examination the species represented by the compound of their Example 7, which is found in Table 1 at page 66 and can be represented by the formula



upon which all of the elected claims are readable. Applicants note that their specification includes excellent test results for the elected species, as shown in Table A at page 79, Table B at page 82, and Table D at page 87. Applicants also note that their specification includes excellent test results for not only the elected species but also for other compounds within their claims, as shown throughout Tables A through E. Therefore, although Applicants believe that the structural and biological relatedness of compounds in which A of the elected species is a pyrazole


within the formula  (with particular reference to compounds 1, 4, 6, 10,

11, 13, 40, 55, and 72, for which test results are shown in the tables), Applicants submit that the generally excellent biological efficacy of compounds of their invention in which group A is a heterocycle other than a pyrazole (for example, thiazole-containing compounds 2, 5, 8, 9, 15, and 69) suggests that examination should extend to at least those embodiments in which group A can be any of the specified five-membered heterocycles having a ring nitrogen atom (that is, where group A is at least the radicals (ix) and (xii) through (xv)). It may be noted that the preparative examples describe other compounds in which group A is a five-membered nitrogen heterocycle, including pyrazoles, thiazoles, isothiazoles, and pyrroles.

In any case, Applicants' election is without traverse to the extent that it is understood that (a) the restriction requirement will be withdrawn upon the finding of an allowable genus and (b) any species withdrawn from consideration will be transferred to the elected subject matter unless found to be patentably distinct from the elected or allowed claims.

In view of the preceding amendments and remarks, allowance of the claims is respectfully requested.

Respectfully submitted,

By 
Richard E. L. Henderson
Attorney for Applicants
Reg. No. 31,619

Bayer CropScience LP
2 T.W. Alexander Drive
Research Triangle Park, NC 27709
Ph.: (919) 549-2183
Fax: (919) 549-3994

Q:patents/prosecution documents/cs8535/8353 amendment 9-30-09